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Introduction
Hormone therapy can improve the quality of life of women with hypo-oestrogenic symptoms 1 . Despite recent data showing that overall health risks may exceed benefits of long-term hormone therapy 2 , many women are still prescribed estrogen therapy to treat postmenopausal climacteric symptoms. Hormone therapy is also effective for preventing osteoporotic fractures among current users 2 3 . By contrast, harmful effects of hormone therapy include breast cancer and venous thromboembolism 4 . Furthermore, randomised controlled trials showed that hormone therapy might increase the risk of coronary heart disease and stroke 2 5 .
Despite evidence that oral oestrogen activates blood coagulation in postmenopausal women 6 , hormone therapy had, until 1996, long been believed to have little effect on the risk of venous thromboembolism 7 . However, observational studies recently showed consistent associations between current use of hormone therapy and an increased risk of venous thromboembolism in postmenopausal women 5 w1-w11 . These findings have been confirmed by randomised controlled trials 5 w12-w20 .
Most previous studies of venous thromboembolism in users of hormone therapy were done among women using conjugated equine oestrogens alone or combined with medroxyprogesterone acetate 8 9 . These results cannot be generalized to other regimens of hormone therapy, especially those used in some European countries.
Recent data have suggested the importance of the route of oestrogen administration in determining risk of venous thromboembolism 10 .
The purpose of this review was to estimate the risk of venous thromboembolism among hormone therapy users. This quantitative assessment takes into account the study design (observational studies or randomized controlled trials) and the characteristics of both hormone therapy (route of oestrogen administration, unopposed or combined with progestogens, duration of treatment) and venous thromboembolism (idiopathic or secondary).
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Methods
Literature search
An electronic search of medical literature was carried out on the MEDLINE database from 1974 to 2007. Relevant keywords relating to hormone therapy (eg, "estrogen replacement" or "oestrogen replacement" or "estrogen" or "estrogen therapy" or "oestrogen" or "oestrogen therapy" or "estrogen replacement therapy" or "oestrogen replacement therapy" or "hormone" or "hormone replacement therapy" or "hormone therapy" or "hormonal therapy" or "hormonal replacement therapy") were used in combination with words relating to venous thromboembolism (eg, "venous thrombosis" or "venous thromboembolism" or "thrombosis" or "pulmonary embolism" or "embolism" or "emboli") We also identified original articles by back-referencing from general reviews published after 1970 7-9 11-17 .
Study selection
We screened all articles identified by key words using Medline Database (n=1890).
We first excluded publications not in English, not related to the topic, on contraception and biological studies. The selected articles (n=111) were reviewed and we excluded general reviews and articles which did not assess venous thromboembolism risk. Twenty four studies (nine randomised controlled trials w12-w20 , twelve case-control studies w1-w3 w5-w7 w9-w11 w21-23 and three prospective cohort studies w4 w24-w25 ) were eligible for inclusion in meta-analysis and were assessed for quality.
Quality assessment
We assessed the quality of randomized controlled trials and observational studies separately. Regarding randomized controlled trials, we assessed studies for quality of randomization, blinding, reporting of withdrawals, generation of random numbers and concealment of allocation. Trials scored one point for each area addressed, therefore receiving a score between 0 and 5 (highest level of quality) 18 19 . We included in the meta-analysis trials which had a score higher or equal to 4 w12-w20 (Table 1) . We assessed the quality of observational studies using a specific checklist consistent with the consensus recommendations by the Meta-analysis Of Observational Studies in Epidemiology MOOSE group 20 . Case-control studies received a score between 0
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5/34 and 6 (highest level of quality) and we included in the meta-analysis studies which had a score higher or equal to 5 w1 w3 w5 w9-w11 w21 (Table 2) . Cohort studies received a score between 0 and 7 (highest level of quality) and we included in the meta-analysis studies which had a score higher or equal to 6 w4 (Table 3 ) (see Quality assessment in appendix).
Data extraction
Included studies were independently reviewed by two authors (PYS and MC).
Disparities were resolved by discussion.
Study characteristics
Each study was classified according to the design (either observational study or randomised controlled trials). Relevant data on the characteristics of hormone therapy (route of oestrogen administration, type of oestrogens, unopposed or opposed hormone regimen, duration of treatment) as well as the characteristics of venous thromboembolism (idiopathic or secondary, deep vein thrombosis or pulmonary embolism, ascertainment of venous thromboembolism) were extracted and used to provide an overall estimate.
Statistical methods
For each study, the most adjusted relative risks (RR) or odds ratios (OR) and their 95% confidence interval (95% CI) were used. Homogeneity between the studies was analyzed using the ² and I² statistics 21 22 . The results of homogenous studies were pooled and an overall estimate of relative risk was obtained from a fixed-effects model 23 . Briefly, a weighted average of relative risks was calculated, with the weights being the inverse of variance of relative risk 24 . For each study, the variance of relative risk was estimated from the 95% confidence interval. When between studies heterogeneity was detected, a random-effects model was used 23 . Statistical analyses were performed using SAS statistical software (version 9.1, SAS Institute Inc, Cary, NC).
Results
Characteristics of the studies
General characteristics of subjects, sample size and types of treatment were studied for each observational study and randomized controlled trial.
 Observational studies
We selected seven case-control studies w1 w3 w5 w9-w11 w21 and one cohort study w4 ( figure 1 and appendix) . Characteristics of included studies are summarized in the table 4.
All the studies have investigated the risk of venous thromboembolism in relation to oral oestrogen use w1 w3-w5 w9-w11 w21 and four of them have evaluated the risk of venous thromboembolism in relation to transdermal route of oestrogen administration w1 w5 w10 w11 .
With regard to the characteristics of hormone therapy, women were treated by either 17-oestradiol w1 w3 w5 w11 or conjugated equine oestrogens w1 w3-w5 w9 w11 w21 or esterified oestrogen w3 w9 . Women were generally classified as current users if they had used hormone therapy at any time in the past 1 to 6 months before inclusion date.
In most of the studies, the clinical endpoint was a first-time idiopathic venous thromboembolism (i.e. without provoking risk factors 25  Heart and oEstrogen/progestin Replacement Study (HERS) w13 HERS was the first clinical trial designed to investigate the effect of hormone therapy on coronary heart disease recurrence. Starting in 1993, HERS was a multi-centre randomised, double-blind, placebo-controlled trial that enrolled 2763 postmenopausal women (mean age 66.7 years) with an intact uterus. Intervention was 0.625 mg conjugated equine oestrogens plus 2.5 mg medroxyprogesterone acetate or placebo.
Venous thromboembolism was used as a secondary outcome in HERS. Venous thromboembolism occurred in 34 women in the hormone therapy group and in 12 women in the placebo group.
 OEstrogen in Venous ThromboEmbolism Trial (EVTET) w14 EVTET was a randomised double-blind trial, comparing 2 mg oestradiol plus 1 mg norethisterone acetate to placebo in postmenopausal women with previously documented venous thromboembolism. The study was stopped prematurely after a mean follow-up of 1 year and 4 months. More women experienced recurrent venous thromboembolism in the hormone therapy group than in the placebo group (8 and 1, respectively) .
 OEstrogen Replacement and Atherosclerosis trial (ERA) w15 The ERA trial examined the effects of hormone therapy on the progression of coronary atherosclerosis in 309 postmenopausal women who had angiographically verified coronary heart disease. Women were randomly assigned to receive The WISDOM trial was a randomized, double blinded, placebo controlled trial, set up in United Kingdom, Australia and New Zealand to assess the long term risk and
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9/34 benefits of hormone therapy in women aged 50 to 69 years without an arterial disease within the past 6 months before inclusion (n=5692). Women were randomly assigned to receive either conjugated equine oestrogens (0.625 mg per day) alone or conjugated equine oestrogens (0.625 mg per day) plus medroxyprogesterone acetate (2.5 mg per day) or placebo. It was planned to compare conjugated equine oestrogens plus medroxyprogesterone acetate with placebo and conjugated equine oestrogens plus medroxyprogesterone acetate with conjugated equine oestrogens alone. Ten years of treatment were been planned but WISDOM was prematurely closed following publication of the WHI results. After a mean follow-up of 11.9 months, venous thromboembolism occurred in 22 women in the conjugated equine oestrogens plus medroxyprogesterone acetate group and in 3 women in the placebo group. Comparison of conjugated equine oestrogens plus medroxyprogesterone acetate versus conjugated equine oestrogens alone outcomes revealed no significant differences.
Results of the meta-analysis
Pooled risk of venous thromboembolism was assessed from eight observational studies and nine randomized controlled trials. From observational studies, the risk of venous thromboembolism was estimated by route of oestrogen administration. In addition, the risk of venous thromboembolism was estimated according to the characteristics of both treatment (type, duration) and venous thromboembolism (idiopathic or secondary, type of diagnostic).
 Venous thromboembolism risk by characteristics of hormone therapy Figure 2 shows pooled OR of first-time venous thromboembolism in relation to hormone therapy use by study design and route of oestrogen administration. All but one observational studies w21 consistently reported an association between oral oestrogen use and an increased risk of venous thromboembolism w1 w3-w5 w9-w11 . Four of them investigated the impact of transdermal oestrogen use on risk of first episode of venous thromboembolism w1 w5 w10 w11 . Pooled OR (95% CI) for oral and transdermal oestrogen was 2.5 (1.9-3.4) and 1.2 (0.9-1.7), respectively. The upper 95% CI for transdermal use (1.7) was lower than the lowest 95% CI for oral use (1.9).
The association of venous thromboembolism with oral oestrogen use was confirmed by results from randomized controlled trials (pooled OR=2.1; 95%CI: 1.4-3.1). The
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One study suggested that the type of oestrogen might be an important determinant of the risk of venous thromboembolism. In this study, conjugated equine oestrogen was associated with increased risk, whereas esterified oestrogen was not w9 .
Data on the risk of venous thromboembolism in past users of hormone therapy compared with never users were available in four observational studies w1 w4 w10 w11 and showed that past use of hormone therapy was not associated with an increased risk of venous thromboembolism (pooled OR=1.2; 95%CI: 0.9-1.7) (Figure 3 ).
The impact of unopposed and opposed oral oestrogen therapy on the risk of venous thromboembolism has been investigated in six observational studies w1 w3 w5 w9-w11 . No significant difference in the risk of venous thromboembolism was observed between oral oestrogen alone and oral oestrogen/progestogen therapy (pooled OR=2.2; 95%CI: 1.6-3.0 and pooled OR=2.6; 95% CI: 2.0-3.2, respectively).
Finally, the risk of venous thromboembolism has been assessed according to the duration of treatment. Information on duration of oral oestrogen was available in only five case-control studies w1 w3 w5 w10 w11 . Results from these studies showed that the risk of venous thromboembolism was significantly higher within the first year of treatment (pooled OR=4.0; 95% CI: 2.9-5.7 for a duration of hormone therapy less than one year and pooled OR=2.1; 95% CI: 1.3-3.8 for a duration of hormone therapy more than one year, p<0.05) (Figure 3 ).
 Risk of venous thromboembolism by type of diagnosis
When analysis was restricted to the first episode of idiopathic events w1 w3-w5 w10 w11 w21 , the risk of venous thromboembolism in relation to oral oestrogen use substantially increased (pooled OR=3.1; 95% CI: 2.3-4.1), whereas results for transdermal oestrogen use remained unchanged.
Analysis by diagnosis of venous thromboembolism showed no significant difference in the risk of venous thromboembolism between deep vein thrombosis and pulmonary embolism in relation to oral oestrogen use. From observational studies, pooled OR (95% CI) was 2.8 (1.9-4.0) for deep vein thrombosis and 2.7 (1.1-2.5) for
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 Women at high risk for venous thromboembolism
The impact of prothrombotic mutations 26 27 on the risk of venous thromboembolism, with or without hormone therapy, has been investigated in four case-control studies w28-w31 and in both WHI clinical trials w26 w27 . Overall the presence of the Factor V Leiden mutation or prothrombin G20210A mutation increased the risk of venous thromboembolism more than 3-fold (pooled OR=3.3; 95%CI: 2.6-4.1). The combination of thrombogenic mutations and oral oestrogen use, especially conjugated equine oestrogen, with or without progestin, further enhanced the risk of venous thromboembolism (OR=8.0; 95% CI: 5.4-11.9) compared with women without mutations who did not use any treatment. However, in one study, there was no significant difference in the risk of venous thromboembolism between women with factor V Leiden mutation or prothrombin G20210A mutation using transdermal oestrogen and women with a mutation but not using oestrogen (OR= 4.4; 95%CI:
2.0-9.9) w30 ( Figure 4 ).
The association of venous thromboembolism with hormone therapy in relation to elevated body-mass index has been investigated in both the WHI clinical trials w26 w27 and in a case-control study w32 . An elevated body-mass index (overweight or obesity) increased the risk of venous thromboembolism (pooled OR=2.6; 95%CI: 2.1-3.3). In addition, the combination of current oral oestrogen use and an increased body-mass index resulted in a further elevation of the risk of venous thromboembolism (pooled OR=5.4; 95%CI: 2.9-10.0). However, in one study, current use of transdermal oestrogen did not confer an additional risk on women with overweight or obesity w32 ( Figure 5 ).
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Discussion
Principal findings
This meta-analysis of both observational studies and randomised controlled trials shows that current use of oral oestrogen increases two to three times the risk of venous thromboembolism. This elevation is higher within the first year of treatment and more pronounced for women at high thrombotic risk. Overall, with a baseline risk for venous thromboembolism of about 1 per 1000 women-years 28 29 , an additional 1.5 events per 1000 women each year would be expected. Combined analysis of observational studies shows no significant increase in the risk of venous thromboembolism among transdermal oestrogen users.
Strengths of the study
Previous reviews and meta-analysis regarding hormone therapy and risk of venous thromboembolism focused on oral oestrogen use and failed to take into account the route of oestrogen administration 7 11 13 15 . This report provides the first quantitative assessment of the thrombotic risk among oral and transdermal oestrogen users separately. Moreover, the present meta-analysis investigated the impact of hormone therapy by route of oestrogen administration among women at high thrombotic risk.
In two previous reviews 13 15 , the risk of venous thromboembolism among oral oestrogen users who carried prothrombotic mutations was assessed from two casecontrol studies w28-w29 . We updated this meta-analysis by adding data from four studies w26 w27 w30 w31 . With regard to women with overweight or obesity, our metaanalysis is the first to show a substantial increase in the risk of venous thromboembolism among oral estrogen users with elevated body-mass index (overweight or obesity) w26 w27 w32 .
Weaknesses of the study
In the present meta-analysis, assessment of the risk of venous thromboembolism among transdermal oestrogen was based on relatively few data w1 w5 w10 w11 .
Therefore, results should be interpreted with caution and further investigation of transdermal oestrogen is needed. Another limitation of the present report is the lack
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13/34 of data on the impact of progestogens. Although this meta-analysis showed similar risk of venous thromboembolism comparing oral oestrogen alone and opposed oral oestrogen, progestogens have recently emerged as a determinant of the risk of venous thromboembolism. One study reported that the risk of venous thromboembolism was higher in users of opposed oral oestrogen than in users of oral oestrogen alone w10 and the risk of venous thromboembolism was higher in the WHI oestrogen/progestogen clinical trial w18 than in the WHI oestrogen alone clinical trial w19 . In addition, among women recruited in the conjugated equine oestrogens plus medroxyprogesterone acetate versus conjugated equine oestrogens WISDOM trial, there was a suggestion in the opposed oestrogen therapy group of an increase in venous thromboembolism (RR=2.39; 95%CI: 0.62-9.24) w20 . Finally, recent data from one case-control study showed that norpregnane derivatives might increase the risk of venous thromboembolism whereas there was no association of venous thromboembolism with micronised progesterone and pregnane derivatives w11 .
Our meta-analysis of both observational studies and randomised controlled trials showed heterogeneity between studies among oral oestrogen users. An important source of heterogeneity between trials may arise from differences in the duration of treatment. The WISDOM trial, which was closed after a median follow-up of 11.2 months, reported an odds ratio for venous thromboembolism higher than those from other randomised controlled trials w20 . When analysis was restricted to randomised trials with a longer follow-up, heterogeneity between studies disappeared. Explanations for heterogeneity between observational studies include differences in the type of venous thrombotic event. Two studies included women with non-idiopathic venous thromboembolism w4 w9 . If analysis was restricted to idiopathic venous thromboembolism, heterogeneity between observational studies disappeared. There were also differences in results by study design. The association of venous thromboembolism with oral oestrogen use was lower in randomized controlled trials than in observational studies. This difference could be explained by inclusion of procedure-related venous thromboembolism in WHI trials, as well as the high degree of nonadherence to study medication in randomized controlled trials, resulting in an underestimation of hormone effects in randomized controlled trials.
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Biological explanations for results
Biological evidence lends support to the difference in the risk of venous thromboembolism between oral and transdermal oestrogen. Oral oestrogen administration results in a hepatic first-pass effect and may impair the balance between procoagulant factors and antithrombotic mechanisms 30 . Oral, but not transdermal, oestrogen increases plasma concentrations of prothrombin fragment 1+2 31 32 , which is a marker for in-vivo thrombin generation, and increases the fibrinolytic potential in postmenopausal women. A lower antithrombin concentration has also been shown in women using oral oestrogen but not in those using transdermal oestrogens 33 . In addition, an acquired resistance to activated protein C has been demonstrated in users of oral oestrogen 34 35 but two randomised trials recently indicated that these results did not apply to users of transdermal oestrogen 32 36 . Thus, transdermal oestrogen appears to have little or no effect on haemostasis.
Clinical implications
The findings of the present meta-analysis of studies by route of estrogen administration may have important clinical implications. Pulmonary embolism accounts for about one third of the excess incidence of potentially fatal events due to long-term hormone therapy 4 . Therefore, the risk of venous thromboembolism is an important determinant of the benefit/risk profile of hormone therapy, and differences in the risk of venous thromboembolism between types of hormone therapy may have important clinical implications. In addition, since recent guidelines recommend that women are prescribed the lowest effective dose of hormone therapy for the shortest time possible 37 , pulmonary embolism becomes a main adverse effect due to oral oestrogen therapy within the first year of treatment. By contrast, there is little increase risk of stroke and breast cancer within the first year of treatment. Therefore, reducing venous thromboembolism risk by transdermal oestrogen use could improve the benefit/risk profile of hormone therapy, especially among women at high risk of venous thromboembolism (e.g. known prothrombotic mutation, elevated body-mass index). Lessons from the Estrogen and Thromboembolism Risk study. Circulation 2007;115 (7):820-2.
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"What this study add" box
What is already known on this topic
Hormone therapy improves the quality of life but it is known to increase the risk of venous thromboembolism.
What this study adds
Transdermal oestrogen decreases the risk of venous thromboembolism when compared to oral oestrogen and it appears safe with respect to thrombotic risk.
Women with prothrombotic mutations or elevated body-mass index are at high risk of venous thromboembolism and should be discouraged from using oral oestrogen therapy.
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